RSS

acid sphingomyelinase deficiency (ASMD)

Sanofi and subsidiary Genzyme have announced that the FDA has granted Breakthrough Therapy designation to olipudase alfa, an enzyme replacement therapy being investigated for the treatment of patients with non-neurological manifestations of ASMD... more

News